{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:23:50Z","timestamp":1790133830177,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2024-2-4011"],"award-info":[{"award-number":["2024-2-4011"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-010"],"award-info":[{"award-number":["2024-I2M-C&T-B-010"]}]},{"name":"Peking Union Medical College Hospital Outstanding Young Talent Development Program","award":["UBJ10659"],"award-info":[{"award-number":["UBJ10659"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B029"],"award-info":[{"award-number":["2022-PUMCH-B029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravascular large B-cell lymphoma (IVLBCL) is an ultra-orphan disease (incidence 0.095\/million\/year) with dismal prognosis due to delayed diagnosis and limited therapeutic options. We aimed to evaluate a novel diagnostic algorithm and the efficacy of zanubrutinib-containing therapy in a real-world Chinese cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective study enrolled 54 IVLBCL patients (2010\u20132022). Diagnostic approaches evolved from PET\/CT-guided biopsy to a combination of serum interleukin-10 (IL-10, cut-off 95.65 pg\/mL), random skin biopsy (RSB), and circulating tumor DNA (ctDNA) profiling. Treatment regimens shifted from R-CHOP to methotrexate-based therapy (MTX), then to zanubrutinib plus R-CHOP (ZR-CHOP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort exhibited distinct features: 35.2% Asian-variant IVLBCL, 50% CNS involvement, and 22.9% PET\/CT negativity. IL-10 combined with RSB enabled the diagnosis of 11 PET\/CT-negative patients who would have otherwise remained undiagnosed. ctDNA revealed\n                      <jats:italic>MYD88 L265P<\/jats:italic>\n                      (11\/17, 65%) and\n                      <jats:italic>CD79B<\/jats:italic>\n                      (7\/17, 41%) variants. ZR-CHOP (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) achieved significantly superior 2-year progression-free survival (PFS) compared to R-CHOP alone (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) (90% vs. 30%; hazard ratio [HR] 0.031,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and demonstrated 100% central nervous system (CNS) relapse-free survival. The efficacy of ZR-CHOP was comparable to that of methotrexate (MTX)-based therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920; 2-year PFS 85%), despite a shorter median follow-up (20.1 vs. 38.0 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this largest Asian IVLBCL cohort to date, IL-10\u2009+\u2009RSB\u2009+\u2009ctDNA significantly improved diagnostic accuracy. Zanubrutinib demonstrated promising efficacy, particularly in CNS involvement, offering a pragmatic solution for this orphan disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04226-4","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:05:22Z","timestamp":1770797122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Breaking diagnostic and therapeutic barriers in intravascular large B-cell lymphoma: A 13-year real-world study from China"],"prefix":"10.1186","volume":"21","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"4226_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1287363","volume":"58","author":"DJ Rajyaguru","year":"2017","unstructured":"Rajyaguru DJ, Bhaskar C, Borgert AJ, Smith A, Parsons B. Intravascular large B-cell lymphoma in the united States (US): a population-based study using Surveillance, Epidemiology, and end results program and National cancer database. Leuk Lymphoma. 2017;58:1\u20139.","journal-title":"Leuk Lymphoma"},{"key":"4226_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"4226_CR3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1182\/blood-2017-04-737445","volume":"132","author":"M Ponzoni","year":"2018","unstructured":"Ponzoni M, Campo E, Nakamura S. Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood. 2018;132:1561\u20137.","journal-title":"Blood"},{"key":"4226_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0002-9343(02)01378-5","volume":"114","author":"S Gill","year":"2003","unstructured":"Gill S, Melosky B, Haley L, ChanYan C. Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. Am J Med. 2003;114:56\u20138.","journal-title":"Am J Med"},{"key":"4226_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1034\/j.1600-0560.2000.027008413.x","volume":"27","author":"T Kiyohara","year":"2000","unstructured":"Kiyohara T, Kumakiri M, Kobayashi H, Shimizu T, Ohkawara A, Ohnuki M. A case of intravascular large B-cell lymphoma mimicking erythema nodosum: the importance of multiple skin biopsies. J Cutan Pathol. 2000;27:413\u20138.","journal-title":"J Cutan Pathol"},{"key":"4226_CR6","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1182\/blood-2018-11-887570","volume":"133","author":"K Matsue","year":"2019","unstructured":"Matsue K, Abe Y, Kitadate A, Miura D, Narita K, Kobayashi H, et al. Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma. Blood. 2019;133:1257\u20139.","journal-title":"Blood"},{"key":"4226_CR7","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.3324\/haematol.2017.178830","volume":"103","author":"Y Suehara","year":"2018","unstructured":"Suehara Y, Sakata-Yanagimoto M, Hattori K, Nanmoku T, Itoh T, Kaji D, et al. Liquid biopsy for the identification of intravascular large B-cell lymphoma. Haematologica. 2018;103:e241\u20134.","journal-title":"Haematologica"},{"key":"4226_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00277-021-04572-2","volume":"101","author":"H Hosoi","year":"2022","unstructured":"Hosoi H, Tanigawa I, Kosako H, Okamoto A, Iwamoto R, Koh J, et al. Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone. Ann Hematol. 2022;101:709\u201311.","journal-title":"Ann Hematol"},{"key":"4226_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1365-2141.2008.07338.x","volume":"143","author":"AJ Ferreri","year":"2008","unstructured":"Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalb\u00e1n C, Horvath B, et al. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in \u2018Western\u2019 patients with intravascular large B-cell lymphoma. Br J Haematol. 2008;143:253\u20137.","journal-title":"Br J Haematol"},{"key":"4226_CR10","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1200\/JCO.2008.19.1841","volume":"26","author":"AJ Ferreri","year":"2008","unstructured":"Ferreri AJ, Dognini GP, Govi S, Crocchiolo R, Bouzani M, Bollinger CR, et al. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26:5134\u20136. author reply 6\u20137.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4226_CR11","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1200\/JCO.2007.15.4278","volume":"26","author":"K Shimada","year":"2008","unstructured":"Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncology: Official J Am Soc Clin Oncol. 2008;26:3189\u201395.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4226_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","volume":"21","author":"K Shimada","year":"2020","unstructured":"Shimada K, Yamaguchi M, Atsuta Y, Matsue K, Sato K, Kusumoto S, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed intravascular large B-cell lymphoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:593\u2013602.","journal-title":"Lancet Oncol"},{"key":"4226_CR13","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1002\/ctm2.131","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Wang L, Sun J, Wang W, Wei C, Zhou D, et al. Serum interleukin-10 as a valuable biomarker for early diagnosis and therapeutic monitoring in intravascular large B-cell lymphoma. Clin Translational Med. 2020;10:e131.","journal-title":"Clin Translational Med"},{"key":"4226_CR14","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.25723","volume":"95","author":"W Wang","year":"2020","unstructured":"Wang W, Zhang Y, Zhang L, Yang C, Feng J, Cai H, et al. Intravenous methotrexate at a dose of 1\u00a0g\/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study. Am J Hematol. 2020;95:E80\u20133.","journal-title":"Am J Hematol"},{"key":"4226_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jdin.2022.09.005","volume":"9","author":"M Takigawa","year":"2022","unstructured":"Takigawa M, Yamasaki O, Nomura H, Miyake T, Yanai H, Morizane S. Probability scoring system of intravascular large B-cell lymphoma for the application of random skin biopsy: A retrospective cohort study. JAAD Int. 2022;9:146\u201352.","journal-title":"JAAD Int"},{"key":"4226_CR16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MPH.0b013e3182431e02","volume":"34","author":"K Mellgren","year":"2012","unstructured":"Mellgren K, Hedegaard CJ, Schmiegelow K, M\u00fcller K. Plasma cytokine profiles at diagnosis in pediatric patients with non-hodgkin lymphoma. J Pediatr Hematol Oncol. 2012;34:271\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"key":"4226_CR17","doi-asserted-by":"publisher","first-page":"e2284","DOI":"10.1210\/clinem\/dgac131","volume":"107","author":"K Yu","year":"2022","unstructured":"Yu K, Xie W, Zhao L, Wang H, Ren Y, Zheng C, et al. sIL-2R: A novel diagnostic biomarker for primary adrenal lymphoma. J Clin Endocrinol Metab. 2022;107:e2284\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"4226_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40364-022-00401-4","volume":"10","author":"YJ Huo","year":"2022","unstructured":"Huo YJ, Xu PP, Wang L, Zhong HJ, Fu D, Shi Q, et al. Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. Biomark Res. 2022;10:51.","journal-title":"Biomark Res"},{"key":"4226_CR19","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","volume":"131","author":"AMR Schrader","year":"2018","unstructured":"Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood. 2018;131:2086\u20139.","journal-title":"Blood"},{"key":"4226_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood.2020007245","volume":"137","author":"K Shimada","year":"2021","unstructured":"Shimada K, Yoshida K, Suzuki Y, Iriyama C, Inoue Y, Sanada M, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood. 2021;137:1491\u2013502.","journal-title":"Blood"},{"key":"4226_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/PAS.0000000000001978","volume":"47","author":"B Gonzalez-Farre","year":"2023","unstructured":"Gonzalez-Farre B, Ramis-Zaldivar JE, Castrej\u00f3n de Anta N, Rivas-Delgado A, Nadeu F, Salmeron-Villalobos J, et al. Intravascular large B-Cell lymphoma genomic profile is characterized by alterations in genes regulating NF-\u03baB and immune checkpoints. Am J Surg Pathol. 2023;47:202\u201311.","journal-title":"Am J Surg Pathol"},{"key":"4226_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"4226_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and prednisone in Non-Germinal center B-Cell diffuse large B-Cell lymphoma. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4226_CR24","doi-asserted-by":"publisher","first-page":"760405","DOI":"10.3389\/fonc.2021.760405","volume":"11","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Li Y, Zhuang Z, Wang W, Wei C, Zhao D, et al. Preliminary evaluation of Zanubrutinib-Containing regimens in DLBCL and the cerebrospinal fluid distribution of zanubrutinib: A 13-Case series. Front Oncol. 2021;11:760405.","journal-title":"Front Oncol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04226-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:04:46Z","timestamp":1781633086000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04226-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04226-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Peking Union Medical College Hospital (I-22PJ1139) on 30 December 2022. The requirement for written informed consent was waived for this retrospective analysis by the same ethics committee due to the use of anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}